Table 1. Demographics and clinical features of the different study groups.

	Phase 1		Phase 2		P value
	SFVE (n = 330)	FUSE (n = 330)	SFVE (n = 330)	FUSE (n = 330)
Age (yrs), mean±SD	60.5 ± 12.5	59.5 ± 13.8	59.6 ± 12.8	60.5 ± 13.6	0.674
Male sex, % ( n )	178 (53.9)	182 (55.2)	181 (54.8)	185 (56.1)	0.959
Indications, % ( n )
Screening	29.7 % (98)	27.9 %(92)	29.1 %(96)	34.8 %(115)	0.219
Bleeding	22.7 % (75)	25.2 %(83)	22.4 % (74)	23.9 % (79)	0.837
Post-polypectomy	22.1 % (73)	22.7 % (75)	22.7 % (75)	15.5 % (51)	0.056
Gastrointestinal symptoms	25.5 % (84)	24.2 % (80)	25.8 % (85)	25.8 %(85)	0.965

SFVE, standard forward-viewing endoscope; FUSE, full-spectrum endoscope